Acute Lymphoblastic Leukemia Market to Surpass USD 4.5 billion with CAGR 7.6% by 2031,TMR Report
05 oct. 2023 07h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The acute lymphoblastic leukemia market was estimated to have acquired US$ 2.2 billion in...
Acute Lymphoblastic Leukemia Market Size to Surpass USD 4.5 billion by 2031, globally, expanding at a CAGR of 7.6%: TMR Report
04 août 2023 10h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The global acute lymphoblastic leukemia market is projected to flourish at a CAGR of 7.6% from 2022 to 2031. As per the report...
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
26 avr. 2023 07h06 HE
|
Autolus Therapeutics plc
- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07 mars 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
NEW LEADING-EDGE TREATMENT FOR LEUKEMIA NOW OFFERED AT NICKLAUS CHILDREN'S HOSPITAL
10 juin 2021 09h54 HE
|
Nicklaus Children's Hospital
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Nicklaus Children's Hospital is one of only a few pediatric hospitals in Florida, and the only one in South Florida, to offer the latest immune cell...
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
05 déc. 2020 15h01 HE
|
Autolus Therapeutics plc
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
16 avr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
07 déc. 2019 14h00 HE
|
Autolus Therapeutics plc
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome Data presented at 61st American Society of Hematology Annual Meeting form...
Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
07 nov. 2019 07h06 HE
|
Autolus Therapeutics plc
LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...